86 related articles for article (PubMed ID: 3223453)
1. [Effectiveness of FUT-175, protease inhibitor, as an anticoagulant to hemodialysis].
Pak K; Shirasu A; Okino K; Sako H; Nakane Y; Umemura K; Maeda S; Tomoyoshi T
Hinyokika Kiyo; 1988 Jun; 34(6):1077-81. PubMed ID: 3223453
[TBL] [Abstract][Full Text] [Related]
2. [Beneficial characteristics of protease inhibitor as an anticoagulant for extracorporeal circulation].
Akizawa T
Rinsho Ketsueki; 1990 Jun; 31(6):782-6. PubMed ID: 2214168
[TBL] [Abstract][Full Text] [Related]
3. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
Akizawa T; Koshikawa S; Ota K; Kazama M; Mimura N; Hirasawa Y
Nephron; 1993; 64(3):376-81. PubMed ID: 8341382
[TBL] [Abstract][Full Text] [Related]
4. Comparative clinical trial of regional anticoagulation for hemodialysis.
Akizawa T; Kitaoka T; Sato M; Koshikawa S; Hirasawa Y; Kazama M; Mimura N; Ota K
ASAIO Trans; 1988; 34(3):176-8. PubMed ID: 3058171
[TBL] [Abstract][Full Text] [Related]
5. The anticoagulant and hemorrhagic effects of DHG, a new depolymerized holothurian glycosaminoglycan, on experimental hemodialysis in dogs.
Minamiguchi K; Kitazato KT; Sasaki E; Nagase H; Kitazato K
Thromb Haemost; 1997 Jun; 77(6):1148-53. PubMed ID: 9241748
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation].
Tsukagoshi S
Gan To Kagaku Ryoho; 2000 May; 27(5):767-74. PubMed ID: 10832450
[TBL] [Abstract][Full Text] [Related]
7. Application of a new anticoagulant (Nafamostat Mesilate) to control hemorrhagic complications during extracorporeal membrane oxygenation--a preliminary report.
Nagaya M; Futamura M; Kato J; Niimi N; Fukuta S
J Pediatr Surg; 1997 Apr; 32(4):531-5. PubMed ID: 9126748
[TBL] [Abstract][Full Text] [Related]
8. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk.
Matsuo T; Kario K; Nakao K; Yamada T; Matsuo M
Haemostasis; 1993; 23(3):135-41. PubMed ID: 8276316
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effect of FUT-175 on complement activation and its application for glomerulonephritis with hypocomplementemia.
Fujita Y; Inoue I; Inagi R; Miyata T; Shinzato T; Sugiyama S; Miyama A; Maeda K
Nihon Jinzo Gakkai Shi; 1993 Apr; 35(4):393-7. PubMed ID: 8341019
[TBL] [Abstract][Full Text] [Related]
10. Plasma collection using nafamostat mesilate and dipyridamole as an anticoagulant.
Hiraishi M; Yamazaki Z; Ichikawa K; Kanai F; Idezuki Y; Onishi K; Takahama T; Inoue N
Int J Artif Organs; 1988 May; 11(3):212-6. PubMed ID: 3403059
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of FUT-175 anticoagulant in adsorbent plasma perfusion.
Yamazaki Z; Hiraishi M; Kanai F; Takahama T; Idezuki Y; Inoue N
ASAIO Trans; 1989; 35(3):567-9. PubMed ID: 2688721
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of nafamstat mesilate (FUT 175). A new anticoagulant for plasmapheresis.
Hosokawa S; Oyamaguchi A; Yoshida O
ASAIO J; 1992; 38(1):59-60. PubMed ID: 1554918
[TBL] [Abstract][Full Text] [Related]
13. [Protease inhibitors as anticoagulant in hemodialysis].
Yamamoto H; Kawaguchi Y; Sakai O
Nihon Rinsho; 1991 Dec; 49 Suppl():741-5. PubMed ID: 1808345
[No Abstract] [Full Text] [Related]
14. [Molecular specificity of nafamostat mesilate (FUT), a drug used for the treatments of DIC and acute pancreatitis and as an anticoagulant--the pharmacodynamics and pharmacological action].
Tsukagoshi S
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1237-43. PubMed ID: 11579633
[TBL] [Abstract][Full Text] [Related]
15. Adsorption of nafamostat mesilate by hemodialysis membranes.
Inagaki O; Nishian Y; Iwaki R; Nakagawa K; Takamitsu Y; Fujita Y
Artif Organs; 1992 Dec; 16(6):553-8. PubMed ID: 1482323
[TBL] [Abstract][Full Text] [Related]
16. Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.
Ikehara S; Shimamura K; Aoyama T; Fujii S; Hamashima Y
Immunology; 1985 Aug; 55(4):595-600. PubMed ID: 4018844
[TBL] [Abstract][Full Text] [Related]
17. Effects of nafamostat mesilate on platelets and coagulofibrinolysis during cardiopulmonary bypass surgery.
Tanaka K; Kondo C; Takagi K; Sato T; Yada I; Yuasa H; Kusagawa M
ASAIO J; 1993; 39(3):M545-9. PubMed ID: 8268595
[TBL] [Abstract][Full Text] [Related]
18. [Effects of new protease inhibitor (FUT-175) on experimental DIC].
Denno R; Hasegawa I; Sasaki K; Gotoh Y; Ebata T; Totsuka M; Hayasaka H
Masui; 1984 Feb; 33(2):125-30. PubMed ID: 6716646
[No Abstract] [Full Text] [Related]
19. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system.
Hitomi Y; Ikari N; Fujii S
Haemostasis; 1985; 15(3):164-8. PubMed ID: 3161808
[TBL] [Abstract][Full Text] [Related]
20. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis.
van Wyk V; Badenhorst PN; Kotzé HF
Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
